A case of multiple lesions of junctional melanocytic hyperplasia arising in a skin graft after excision of a congenital melanocytic naevus is reported. This observation is shown to support the concept of the histogenesis of acquired melanocytic naevi proposed by Cramer [2], i.e. that acquired melanocytic naevi are derived from melanocyte precursors located in nerve sheaths, whereas it is inconsistent with notions of the origin of naevogenesis in the epidermal melanocyte.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s001050050331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers.
J Exp Med
March 2025
Institute of Cancer Research, Shenzhen Bay Laboratory , Shenzhen, China.
BRAF mutations drive initiation and progression of various tumors. While BRAF inhibitors are effective in BRAF-mutant melanoma patients, intrinsic or acquired resistance to these therapies is common. Here, we identify non-receptor-type protein tyrosine phosphatase 23 (PTPN23) as an alternative effective target in BRAF-mutant cancer cells.
View Article and Find Full Text PDFCo-isolation of human donor eye cells and development of oncogene-mutated melanocytes to study uveal melanoma.
BMC Biol
January 2025
Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Background: Uveal melanoma (UM) is the most common intraocular tumor in adults, arises either de novo from normal choroidal melanocytes (NCMs) or from pre-existing nevi that stem from NCMs and are thought to harbor UM-initiating mutations, most commonly in GNAQ or GNA11. However, there are no commercially available NCM cell lines, nor is there a detailed protocol for developing an oncogene-mutated CM line (MutCM) to study UM development. This study aimed to establish and characterize premalignant CM models from human donor eyes to recapitulate the cell populations at the origin of UM.
View Article and Find Full Text PDFThe Pathogenesis and Management of Vitiligo.
Cureus
December 2024
Physiology, Taibah University, Al-Madinah al-Munawarah, SAU.
Vitiligo is a common autoimmune disease that progressively destroys melanocytes in the skin, resulting in the appearance of patchy depigmentation. The aim of this review is to increase awareness towards vitiligo by providing insight on the pathogenesis and management options. Vitiligo is an acquired pigmentary skin disease, which can appear with one or a few macules.
View Article and Find Full Text PDFRecent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.
J Clin Invest
January 2025
Department of Dermatology, UMass Chan Medical School, Worcester, Massachusetts, USA.
Vitiligo is an autoimmune disease that has been recognized, stigmatized, and treated for millennia. Recent translational research has revealed key mechanisms of disease, including cellular stress, innate immune activation, T cell-mediated elimination of melanocytes from the skin resulting in clinically apparent white spots, as well as stem cell regeneration that reverses established lesions. Many of these pathways have been targeted therapeutically, leading to the first FDA-approved medication to reverse the disease, with many more in clinical trials.
View Article and Find Full Text PDFOral Blue Nevus of the Lingual Gingiva: A Case Report.
Cureus
January 2025
College of Dentistry, King Saud University, Riyadh, SAU.
Oral melanocytic nevi (OMN) are rare benign tumors originating from melanocytes with an unclear pathogenesis. The current theory suggests that OMN originate from dormant dendritic melanocytes that become enclosed in the dermis during the embryonic migration of melanoblasts - the precursors of melanocytes - from the neural crest to the epidermis. OMN can be congenital or acquired, with acquired nevi being more common.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!